Benzinga | Nov 5, 2021 09:21AM EDT

Denali Therapeutics Q3 EPS $(0.69) Down From $(0.54) YoY, Sales $5.28M Down From $9.39M YoY

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.69) per share. This is a 27.78 percent decrease over losses of $(0.54) per share from the same period last year. The company reported $5.28 million in sales this quarter. This is a 43.79 percent decrease over sales of $9.39 million the same period last year.